Seeking Alpha

Amarin (AMRN +1.6%) bucks a weak tape this morning after saying that the USPTO has issued two...

Amarin (AMRN +1.6%) bucks a weak tape this morning after saying that the USPTO has issued two patents covering the use of it's VascepaTM capsules for treating Hypertriglyceridemia. The patent issuance is part of AMRN's effort to protect the commercial potential of the drug through 2030, and it plans to list both patents in the FDA's Orange Book.
Comments (6)
  • Does this mean the NCE status is more likely?
    23 Oct 2012, 10:55 AM Reply Like
  • AMRN receives good news, goes up 5 cents... every time there's NCE doubts, goes down $2. Jeez, these traders are freaky.
    23 Oct 2012, 11:05 AM Reply Like
  • Amarin is one of those stocks that can make up lost ground faster than most.....but the train seems to be waiting around still....once it leaves you could miss the bulk of it imo.
    23 Oct 2012, 11:32 AM Reply Like
  • hum dee dum, need this to explode
    23 Oct 2012, 01:00 PM Reply Like
  • FDA could have very well been waiting for the 889 issuance for the support of NCE - reason is b/c it deals w/ specific method of action against the indication , as it relates to EPA only.

     

    I believe NCE approval will be coming shortly.
    23 Oct 2012, 01:19 PM Reply Like
  • This market is hilarious. News about the patents is out before market opens. Big tree shake takes the stock to sub 11 and then we rally hard from there. So comical...
    23 Oct 2012, 01:53 PM Reply Like
DJIA (DIA) S&P 500 (SPY)